Suboptimal Triglyceride Levels Common Among US Adults
Researchers evaluated the prevalence of elevated triglyceride levels in adults with and without statin use and the related 10-year predicted risk for atherosclerotic cardiovascular disease.
Dyslipidemia
Higher Exposure to CVD Risk Factors in Women vs Men Who Have Diabetes
Compared with men, women who have diabetes experience greater changes in the cumulative burden of cardiovascular risk factors from young to middle-age adulthood.
Lipoprotein(a) as Risk Factor in Heterozygous Familial Hypercholesterolemia
Researchers examined whether lipoprotein(a) cholesterol life-years can effectively measure cumulative risk for atherosclerotic cardiovascular disease and questioned whether this metric may apply to the incidence of aortic valve calcification.
Novel Lipid Biomarker HDL3-C Predicts Severity of Coronary Artery Disease
Investigators sought to determine the effect HDL-C subparticles HDL2-C and HDL3-C have on assessing CAD severity in patients who receive statin therapy.
Comorbid Metabolic Syndrome, Psoriatic Arthritis Linked to Reduced Health-Related Quality of Life
Patients with plaque psoriasis have a reduced health-related quality of life, mainly in terms of emotional aspects.
Linagliptin and Cardiovascular Events in Patients With Type 2 Diabetes
Investigators evaluated the effect of linagliptin vs placebo on cardiovascular and kidney disease outcomes in patients with T2D at high risk for cardiovascular and renal events.
Safety of PCSK9 Inhibitors After Heart Transplantation Examined
PCSK9 inhibitors are a potentially safe lipid-lowering therapy for heart transplant recipients with suboptimal LDL management on statins.
Population Health Data May Help Identify Patients at Risk for CVD
Population-level data can help medical practitioners use electronic health records to identify patients at risk for cardiovascular disease.
High-Intensity Statins Affect Coronary Plaque Composition After STEMI
Patients using a high-intensity statin after a STEMI experienced a significant increase in minimum fibrous cap thickness.
Further Reductions in Alirocumab Price Needed to Be Considered Cost-Effective
For alirocumab to be considered cost-effective compared with generic ezetimibe, its annual price would have to be reduced to less than $900.
Next post in Cardiovascular and Metabolic Disorders
